Skip to content
Homepage
Author:
Pliant Therapeutics, Inc.
Posted Date:
July 13, 2026
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
Pliant Therapeutics, Inc.
July 13, 2026
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Pliant Therapeutics, Inc.
May 21, 2026
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Pliant Therapeutics, Inc.
May 11, 2026
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
Pliant Therapeutics, Inc.
May 6, 2026
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Pliant Therapeutics, Inc.
April 30, 2026
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics, Inc.
April 18, 2026
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics, Inc.
March 18, 2026
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
Pliant Therapeutics, Inc.
March 11, 2026
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
Pliant Therapeutics, Inc.
February 23, 2026
